Company news
Zura Bio Limited (NASDAQ:ZURA) news
Zura Bio Limited news releases on 6ix. Latest, Aug 31, 2026: Zura Bio to Participate in the Cantor Global Healthcare Conference
Press releases & updates
Zura Bio to Participate in the Cantor Global Healthcare Conference
August 31, 2026
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
August 11, 2026
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
June 29, 2026
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
May 13, 2026
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
May 7, 2026
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
March 18, 2026
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
March 4, 2026
Zura Bio to Participate in Upcoming Investor Conferences
March 2, 2026
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 27, 2026
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
February 25, 2026
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
February 23, 2026
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
February 23, 2026
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 4, 2026
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
January 21, 2026
Zura Bio Reports Business Updates and Outlook for 2026
January 12, 2026
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
November 13, 2025
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
August 20, 2025
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
August 14, 2025
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2025
Zura Bio Announces Chief Financial Officer Transition
July 1, 2025
Zura Bio to Present at the Jefferies Global Healthcare Conference
May 27, 2025
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
May 20, 2025
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates
May 8, 2025
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
March 25, 2025
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
February 24, 2025
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
December 22, 2024
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
November 13, 2024
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
November 6, 2024
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 12, 2024
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
August 11, 2024
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants
August 8, 2024
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
July 11, 2024
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
June 5, 2024
Zura Bio Announces Participation in June Investor Conferences
May 28, 2024
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 8, 2024
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
April 17, 2024
Zura Bio Announces Robert Lisicki as CEO and Director
April 7, 2024
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
March 27, 2024
Zura Bio Announces Participation at February Investor Conferences
February 1, 2024
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
January 7, 2024
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
December 3, 2023
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
November 13, 2023
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 12, 2023
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
September 11, 2023
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 13, 2023
Zura Bio to Join the Russell 2000® and Russell 3000® Indexes
June 22, 2023
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist
June 5, 2023
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases
April 26, 2023
Zura Bio Announces Appointment of Chief Scientific Officer
April 13, 2023